Physician profile
Jessica Scheick
NPI 1447006085
$3,018.29
in general payments reported to CMS, 2019-2025
19 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $99.98 · 2024: $1,420 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $526.83 | 2024-2025 | Farxiga, Lokelma |
| Amgen INC. | $465.13 | 2024-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $321.91 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $303.15 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $248.99 | 2024-2025 | |
| Ardelyx, INC. | $226.90 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $222.44 | 2024-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.00 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $114.95 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $83.97 | 2025 | Terlivaz, Acthar |
| Vifor Pharma, INC. | $45.57 | 2024-2025 | Veltassa |
| Invivyd INC | $33.12 | 2024 | Pemgarda |
| Apellis Pharmaceuticals, INC. | $29.74 | 2025 | Empaveli |
| Aurinia Pharma U.S., INC. | $27.88 | 2025 | Lupkynis |
| Novo Nordisk INC | $22.25 | 2025 | Ozempic |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $22.03 | 2025 | |
| Nxstage Medical, INC. | $19.61 | 2025 | Nxstage System One, Liberty Select Cycler |
| Glaxosmithkline, LLC. | $15.06 | 2025 | Arexvy |
| Alexion Pharmaceuticals, INC. | $13.78 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Scheick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.